Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers

Joshua T. Kantrowitz, Jack Grinband, Donald C. Goff, Adrienne C. Lahti, Stephen R. Marder, Lawrence S. Kegeles, Ragy R. Girgis, Tarek Sobeih, Melanie M. Wall, Tse Hwei Choo, Michael F. Green, Yvonne S. Yang, Junghee Lee, Guillermo Horga, John H. Krystal, William Z. Potter, Daniel C. Javitt, Jeffrey A. Lieberman

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Fingerprint

Dive into the research topics of 'Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers'. Together they form a unique fingerprint.

Medicine & Life Sciences